We are live on ! Find out more
SLNO

Soleno Therapeutics
SLNO

Delisted

SLNO was delisted on the 15th of May, 2026.

Back to rankings

76 hedge funds and large institutions have $1.27B invested in Soleno Therapeutics in 2023 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 22 increasing their positions, 10 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

183% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 12

120% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 10

111% more capital invested

Capital invested by funds: $599M → $1.27B (+$668M)

41% more funds holding

Funds holding: 54 → 76 (+22)

13% less funds holding in top 10

Funds holding in top 10: 8 → 7 (-1)

38% less call options, than puts

Call options by funds: $2.46M | Put options by funds: $3.98M

100.07% less ownership

Funds ownership: 203.22% → 103.15% (-100%)

Holders
76
Holders Change
+22
Holders Change %
+40.74%
% of All Funds
1.11%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.1%
New
34
Increased
22
Reduced
10
Closed
12
Calls
$2.46M
Puts
$3.98M
Net Calls
-$1.52M
Net Calls Change
-$1.52M

Top Buyers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
+$148M
2
NCM
Nantahala Capital Management
Connecticut
+$70.1M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$26M
4
ACA
Avoro Capital Advisors
New York
+$22.3M
5
CG
Carlyle Group
District of Columbia
+$16.1M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$36.6M
2
FFM
Fairmount Funds Management
Pennsylvania
-$33.7M
3
SCM
Soleus Capital Management
Connecticut
-$9.59M
4
SCM
Silverarc Capital Management
Massachusetts
-$8.43M
5
FCM
Farallon Capital Management
California
-$6.34M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
26
Altium Capital Management
New York
$4.22M +$1.65M +57,828 +123%
Morgan Stanley
27
Morgan Stanley
New York
$4.08M +$1.94M +68,274 +206%
EI
28
EAM Investors
California
$3.76M -$1.31M -45,905 -33%
6CM
29
683 Capital Management
New York
$3.5M – – –
SCM
30
Silverarc Capital Management
Massachusetts
$2.97M -$8.43M -296,335 -80%
JGC
31
J. Goldman & Co
New York
$2.95M +$206K +7,252 +11%
Goldman Sachs
32
Goldman Sachs
New York
$2.76M +$1.95M +68,599 New
SSA
33
Schonfeld Strategic Advisors
New York
$2.45M +$1.07M +37,690 +162%
Bank of America
34
Bank of America
North Carolina
$2.31M +$1.52M +53,572 +1,374%
CSS
35
Cubist Systematic Strategies
Connecticut
$2.29M +$1.62M +57,006 New
Rafferty Asset Management
36
Rafferty Asset Management
New York
$2.09M +$1.48M +51,874 New
Jane Street
37
Jane Street
New York
$1.83M +$1.29M +45,456 New
JFG
38
Jefferies Financial Group
New York
$1.41M +$998K +35,091 New
Citigroup
39
Citigroup
New York
$1.37M +$963K +33,859 +32,873%
Northern Trust
40
Northern Trust
Illinois
$1.34M +$748K +26,288 +374%
MC
41
Maplelane Capital
New York
$1.01M – – –
Swiss National Bank
42
Swiss National Bank
Switzerland
$918K +$649K +22,800 New
Susquehanna International Group
43
Susquehanna International Group
Pennsylvania
$870K +$615K +21,620 New
Barclays
44
Barclays
United Kingdom
$858K +$606K +21,305 New
Dimensional Fund Advisors
45
Dimensional Fund Advisors
Texas
$835K – – –
AIC
46
AWM Investment Company
New York
$805K +$569K +20,000 New
AA
47
ALPS Advisors
Colorado
$784K +$554K +19,486 New
Qube Research & Technologies (QRT)
48
Qube Research & Technologies (QRT)
United Kingdom
$753K +$532K +18,696 New
UBS Group
49
UBS Group
Switzerland
$716K +$506K +17,788 New
Millennium Management
50
Millennium Management
New York
$551K -$1.19M -41,773 -75%
1
2
3 4

SLNO Hedge Fund Activity: Q4 2023 in Review

76 of the 6,865 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q4 2023, worth a combined $1.27B — up 111% from $599M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new SLNO positions and 12 closed out — a net gain of 22 holders — while 22 added to existing stakes and 10 trimmed.

The largest buyer was Vivo Capital, adding an estimated $148M. The largest seller was RA Capital Management, exiting entirely with an estimated $36.6M sold.

  • 76 institutional investors held Soleno Therapeutics (SLNO) as of Q4 2023, up from 54 in Q3 2023.
  • Funds reported $1.27B of Soleno Therapeutics stock for Q4 2023, up 111% quarter-over-quarter.
  • 34 funds opened new Soleno Therapeutics positions in Q4 2023 and 12 closed out, a net change of +22 holders.
  • The largest Soleno Therapeutics buyer in Q4 2023 was Vivo Capital, an estimated $148M added.
  • The largest Soleno Therapeutics seller in Q4 2023 was RA Capital Management, an estimated $36.6M sold.

Based on aggregated 13F filings for Q4 2023.